Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome

Area of Science:

• Oncology
• Genetics
• Hematology

Background:

• Hematologic malignancies (HMs) represent a significant cancer type in Li-Fraumeni syndrome (LFS).
• The full spectrum and outcomes of HMs in LFS patients are not well-defined.

Purpose of the Study:

• To characterize the phenotypic spectrum and clinical outcomes of hematologic malignancies in individuals with Li-Fraumeni syndrome.

Main Methods:

• Retrospective cohort study of LFS families with HMs at two institutions.
• Literature review to identify additional LFS patients with HMs.
• Analysis of HM molecular characteristics, treatment, and outcomes.

Main Results:

• 17 of 121 LFS families (13%) had HMs; 99 total patients (including literature review) identified.
• HM spectrum included 10 subtypes, with a higher incidence of lymphoid than myeloid malignancies.
• Most HMs were de novo, not post-cytotoxic therapy, and responded to standard treatments, though some experienced unusual toxicities, particularly after stem-cell transplantation.

Conclusions:

• Li-Fraumeni syndrome is associated with a wide range of hematologic malignancies.
• Lymphoid HMs are more common than myeloid HMs in LFS.
• Outcomes for HMs in LFS appear more favorable than previously suggested, with a lower incidence of post-therapy malignancies.